MEDVi QUAD vs Rugiet Ready: QUAD's New Formula Changed This Comparison — Here's What Actually Matters

QUAD and Rugiet are the two serious contenders in the multi-ingredient sublingual ED space. Both are built on the same PDE5 inhibitor core — sildenafil and tadalafil. Both skip the pill format. But after QUAD's July 2026 reformulation, the two products take genuinely different paths from that shared foundation, and the differences — in what's inside, how they're delivered, and what they cost — are bigger than most comparison articles let on. We dug into the clinical literature, user reviews, and pricing structures to figure out which one makes more sense, and for whom.

The ingredient split is the whole story

If you strip away the marketing, both products start from the same place: sildenafil plus tadalafil, the two workhorse PDE5 inhibitors. What each one builds on top of that shared core is where the real difference lives.

Rugiet Ready combines sildenafil, tadalafil, and apomorphine. It was the first product to do this when it launched in 2020, and it deserves credit for creating the category. Two PDE5 inhibitors plus a dopamine agonist for the desire side. It works well for a lot of men, and the formula hasn't changed.

QUAD used to play a similar game — its original formula included apomorphine too, plus vardenafil. But in July 2026, MEDVi reformulated. Vardenafil and apomorphine are out. In their place: L-citrulline and PT-141. L-citrulline is an amino acid that converts to L-arginine in the body, raising nitric-oxide production — the exact pathway PDE5 inhibitors depend on to work. A small single-blind clinical study (Cormio et al., Urology, 2011) found oral L-citrulline improved erection hardness in 50% of men with mild ED versus 8% on placebo. It's a supplement-grade amino acid, not an FDA-approved ED drug — call it a nitric-oxide amplifier with early but genuine clinical evidence.

PT-141 (bremelanotide) is the more interesting swap. Where apomorphine hits the dopamine system, PT-141 activates melanocortin receptors in the brain — targeting sexual desire and arousal centrally rather than blood flow. It's FDA-approved as Vyleesi (2019) for low sexual desire in premenopausal women, and early-phase male trials of intranasal bremelanotide showed erectogenic effects, including in some sildenafil non-responders. It was never approved for ED — development stopped partly over blood-pressure concerns — and its use in QUAD is off-label, compounded, and prescriber-supervised. Notably, apomorphine — a dopamine agonist also used in Parkinson's disease — drew media scrutiny in 2026; QUAD no longer contains it, while Rugiet still does. That's a fact, not an accusation — apomorphine remains part of Rugiet's established, physician-prescribed formula.

To put it plainly: same PDE5 engine on both sides. Rugiet backs it with a dopamine-based desire ingredient. QUAD backs it with a nitric-oxide amplifier plus a desire-pathway peptide that has human trial data and an FDA approval in another indication. The question is which supporting cast you'd rather have.

The format difference matters more than you'd think

Rugiet Ready is a sublingual troche — a solid lozenge that you place under your tongue and let dissolve over 5–10 minutes. In theory, this works well. In practice, there's a problem.

Rugiet asks you to store its troches in a cool, dry place at room temperature — 74°F (23°C) or below. That's a normal indoor temperature, but a car in summer or a pocket through a long dinner will beat it, and the troche can soften or melt. Rugiet's guidance for that is specific: if a dose melts in transit and the blister pack is intact, put it in the refrigerator until it firms up, then use it normally. Refrigeration is the remedy for a soft delivery, not a standing storage requirement, and Rugiet does not ask you to keep the product chilled.

The part worth being straight about is what melting actually costs you. Rugiet states plainly that melting or freezing does not alter the active ingredients in Rugiet Ready; what excessive heat affects is the tablet's texture and handling. So a softened troche is awkward — messier to handle, harder to split accurately, and it may need a spell in the fridge before you can use it — but on the manufacturer's own account the medicine in it is unchanged.

QUAD avoids that inconvenience by being a liquid to begin with. You measure the dose with a dropper, place it under your tongue, hold for 60–90 seconds, done. Nothing to soften, and no step where you have to firm anything up first.

The liquid format also has a pharmacokinetic advantage. With a troche, the drug needs to dissolve first before it can be absorbed through the sublingual membrane. With a liquid, the active ingredients are already in solution — absorption begins immediately on contact. This likely accounts for QUAD's slightly faster onset (10–15 minutes vs Rugiet's 15 minutes).

Pricing: harder to line up than it looks

The two companies don't price the same way, which makes a straight comparison impossible. Rugiet publishes a starting per-dose figure and no monthly one; MEDVi publishes a monthly subscription price.

At the entry price, a few doses a month lands well under QUAD's $119 — but that is the cheapest strength, and Rugiet doesn't say what higher strengths or larger packs cost, so you won't know your real monthly outlay until you've completed the consultation and chosen one. QUAD's $119 is at least a fixed, knowable number, though MEDVi doesn't publish per-ingredient amounts either, so per-dose math isn't clean on that side.

Neither product is cheap compared to popping a generic sildenafil pill for $3. But neither product is trying to be that. These are premium combination treatments for men who've moved past the single-ingredient phase.

Where Rugiet still wins

This wouldn't be an honest comparison if we didn't acknowledge what Rugiet does better.

Track record and reviews

Rugiet has been on the market since 2020. They have 1,594 Trustpilot reviews averaging 4.3 out of 5 (July 2026). That's a real body of evidence from real users. QUAD is newer with a smaller user base — roughly 5,000 users. The product science is strong, but the user validation is still catching up. For men who want to see thousands of people confirm "yes, this works" before committing, Rugiet has a substantial lead.

Dosing customization

Rugiet's physicians can adjust the ratio of each ingredient — increasing sildenafil while reducing tadalafil, for example, or fine-tuning the apomorphine dose. They offer four documented strength tiers and the flexibility to go beyond them based on patient feedback. QUAD offers clinician-guided dosing, but the level of documented customization granularity isn't as detailed in their public materials.

Brand recognition

If you mention Rugiet in a men's health forum, people know what it is. QUAD is still building that name recognition. This doesn't affect how the medication works, but it does affect how comfortable some men feel trying it.

Side effects: a shared baseline, then a fork

Both products share the same PDE5 core (sildenafil and tadalafil), so the baseline side effect profile overlaps: headache, nasal congestion, facial flushing, occasional dizziness. From there the profiles fork with the formulas. Rugiet's apomorphine can cause mild nausea. QUAD no longer contains apomorphine — its added ingredients are L-citrulline, a supplement-grade amino acid, and PT-141, whose ED development program was halted partly over blood-pressure concerns, which is one reason its use here is off-label and prescriber-supervised.

Both products are compounded, so exact ingredient amounts are set by the prescribing physician rather than fixed for everyone — clinicians can dial individual components up or down based on response.

Both products are contraindicated with nitrate medications. Both require a clinician review before prescribing.

Who should choose which

Our bottom line

Both products work. Both are legitimate compounded ED medications prescribed through telehealth platforms. The decision comes down to what you prioritize.

Rugiet Ready is the proven choice. It's been on the market since 2020, it has a mountain of user reviews, and the customization options are genuinely useful for men who need precise dose titration. Its weaknesses — troches that can soften in the heat, and pricing that stops at a starting per-dose figure — are real but not dealbreakers.

QUAD is the more novel product, especially after its July 2026 reformulation. Every ingredient in the new formula has published human clinical evidence for sexual function, it's the only option here with a desire-pathway ingredient carrying an FDA approval in any form, and the liquid delivery means no temperature sensitivity at competitive pricing. Its weakness is newness — fewer user reviews, less brand recognition, and a formula that's only months old. But the ingredient logic is coherent, and the liquid format solves a real practical problem that affects Rugiet daily.

For men who've tried Rugiet and are happy with it, stay. For men making a fresh decision, or for anyone who's been frustrated by Rugiet's limitations, QUAD is worth a serious look.

Frequently Asked Questions

More Comparisons & Reviews